Adjunctive lamotrigine for refractory epilepsy in adolescents with mental retardation

Journal of Child Neurology

Volumn 21, Issue 5, 2006, Pages 372-379

  McKee, Jerry R ^a,d   Sunder, Theodore R ^b   Vuong, Alain ^c   Hammer, Ann E ^c  

^a Western Carolina Center   (United States)

^b SOUTHERN ILLINOIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c GLAXOSMITHKLINE   (United States)

^d Broughton Hospital   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; CARBAMAZEPINE; GABAPENTIN; LAMOTRIGINE; VALPROIC ACID;

ABDOMINAL PAIN; ADJUVANT THERAPY; ADOLESCENT; ADULT; ARTICLE; CHILD BEHAVIOR; CLINICAL ARTICLE; COMORBIDITY; COMPLEX PARTIAL SEIZURE; DAILY LIFE ACTIVITY; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DISEASE SEVERITY; DIZZINESS; DOSE RESPONSE; DRUG ERUPTION; DRUG SAFETY; DRUG TOLERABILITY; EPILEPSY; FEMALE; FOCAL EPILEPSY; HUMAN; MALE; MENTAL DEFICIENCY; OPEN STUDY; OUTCOMES RESEARCH; PREDICTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK REDUCTION; SCORING SYSTEM; SOMNOLENCE; TONIC CLONIC SEIZURE; TREATMENT RESPONSE; VOMITING;

EID: 33745942700     PISSN: 08830738     EISSN: None     Source Type: Journal    
DOI: 10.1177/08830738060210051401     Document Type: Article

References (45)

1. Pellock JM, Morton LD: Treatment of epilepsy in the multiply handicapped. Meat Retard Dev Disabil 2000;6:309-323.
2. Coulter DL: Comprehensive management of epilepsy in persons with mental retardation. Epilepsia 1997;38(Suppl 4):S24-S31.
3. Sunder TR: Meeting the challenge of epilepsy in persons with multiple handicaps. J Child Neurol 1997;12(Suppl 1):S38-S43.
4. Dodson WE: Epilepsy, cerebral palsy, and other issues, in Pellock JM, Dodson WE, Bourgeois BFD (ads): Pediatric Epilepsy: Diagnosis and Therapy. New York, Demos, 2001, 613-627.
5. Hauser WA: Epidemiology of epilepsy in children, in Pellock JM, Dodson WE, Bourgeois BFD (eds): Pediatric Epilepsy: Diagnosis and Therapy. New York, Demos, 2001, 81-96.
6. Fisher RS, Kerrigan JF: Other new antiepileptic drugs, in Pellock JM, Dodson WE, Bourgeois BFD (eds): Pediatric Epilepsy: Diagnosis and Therapy. New York, Demos, 2001, 513-540.
7. Coppola G, Pascotto A: Lamotrigine as add-on drug in children and adolescents with refractory epilepsy and mental delay: An open trial. Brain Dev 1997;19:398-402.
8. Huber B, May T, Seidel M: Lamotrigine in multi-handicapped, therapy-resistant epileptic patients. Clin Drug Invest 1998;16:263-277.
9. Gidal BE, Walker JK, Lott RS, et al: Efficacy of lamotrigine in institutionalized, developmentally disabled patients with epilepsy: A retrospective evaluation. Seizure 2000;9:131-136.
10. Uvebrant P, Bauzien PR: Intractable epilepsy in children. The efficacy of lamotrigine treatment, including non-seizure-related benefits. Neuropediatrics 1994;25:284-289.
11. Motte J, Trevathan E, Arvidsson JFV, et al: Lamotrigine for generalized seizures associated with the Lennox-Gastaut syndrome. N Engl J Med 1998;337:1807-1812.
12. Timmings PL, Richens A: Lamotrigine as an add-on drug in the management of Lennox-Gastaut syndrome. Eur Neurol 1992;32:305-307.
13. Veggiotti P, Cieuta C, Rey E, et al: Lamotrigine in infantile spasms. Lancet 1994;344:1375-1376.
14. Franz DN, Tudor C, Leonard J, et al: Lamotrigine therapy of epilepsy in tuberous sclerosis. Epilepsia 2001;42:935-940.
15. Uldall P, Hansen FJ, Tonnby B: Lamotrigine in Rett syndrome. Neuropediatrics 1993;24:339-340.
16. Stenbom Y, Tonnby B, Hagberg B: Lamotrigine in Rett syndrome: Treatment experience from a pilot study. Eur Child Adolesc Psychiatry 1998;7:49-52.
17. Aldenkamp AP: Cognitive side effects of antiepileptic drugs, in Pellock JM, Dodson WE, Bourgeois BFD (eds): Pediatric Epilepsy: Diagnosis and Therapy. New York, Demos, 2001, 629-635.
18. Brodie MJ, Richens A, Yuen AWC, et al: Double-blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy. Lancet 1995;345:476-479.
19. Steiner TJ, Dellaportas CI, Findley LJ: Lamotrigine monotherapy in newly diagnosed untreated epilepsy: A double-blind comparison with phenytoin. Epilepsia 1999;40:601-607.
20. Biton V, Mirza W, Montouris G, et al: Weight change associated with valproate and lamotrigine monotherapy in patients with epilepsy. Neurology 2001;56:172-177.
21. Besag FMC, Dulac O, Alving J, et al: Long-term safety and efficacy of lamotrigine in pediatric patients with epilepsy. Seizure 1997;6:51-56.
22. Messenheimer JA, Giorgi L, Risner ME: The tolerability of lamotrigine in children. Drug Saf 2000;22:303-312.
23. Duchowney M. Pellock JM, Graf WD, et al: A placebo controlled trial of lamotrigine add-on therapy for partial seizures in children. Neurology 1999;53:1724-1731.
24. Messenheimer J: Efficacy and safety of lamotrigine in pediatric patients. J Child Neurol 2002:17(Suppl 2):2S34-2S42.
25. Petersen AC, Leffert N: Developmental issues influencing guidelines for adolescent research: A review. J Adolesc Health 1995;17:298-305.
26. Commission on Classification and Terminology of the International League Against Epilepsy: Proposal for revised clinical and electroencephalographic classification of epileptic seizures. Epilepsia 1989;30:389-399.
27. American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, 4th Edition, Revised. Washington, DC, American Psychiatric Association, 1994.
28. McKee JR, Sunder TR, FineSmith R, et al: Lamotrigine as adjunctive therapy in patients with refractory epilepsy and mental retardation. Epilepsy Behav 2003;4:386-394.
29. Aman MG, Singh NN, Turbott SH: Reliability of the Aberrant Behavior Checklist and the effect of variation in instructions. Am J Ment Defic 1987;92:237-240.
30. Bodfish JW: The Habilitative Improvement Scale. Western Carolina Center Research Reports. Morganton, NC, Western Carolina Center, 1996.
31. Buchanan N: The efficacy of lamotrigine on seizure control in 34 children, adolescents and young adults with intellectual and physical disability. Seizure 1995;4:233-236.
32. Messenheimer JA, Mullens EL, Giorgi L, et al: Safety review of adult clinical trial experience with lamotrigine. Drug Saf 1998;18:281-296.
33. Smith D, Baker G, Davies G, et al: Outcomes of add-on treatment with lamotrigine in partial epilepsy. Epilepsia 1993;34:312-322.
34. Marciani MG, Stanzione P, Mattia D, et al: Lamotrigine add-on therapy in focal epilepsy: Electroencephalographic and neuropsychological evaluation. Clin Neuropharmacol 1998;21:41-47.
35. Edwards KR, Sackellares JC, Vuong A, et al: Lamotrigine monotherapy improves depressive symptoms in epilepsy: A double-blind comparison with valproate. Epilepsy Behav 2001;2:28-36.
36. Pellock JM: Lamotrigine, in Pellock JM, Dodson WE, Bourgeois BFD (eds): Pediatric Epilepsy: Diagnosis and Therapy. New York, Demos, 2001, 461-466.
37. Steiner TJ, Silviera C, Yuen AWC: Comparison of lamotrigine and phenytoin monotherapy in newly diagnosed epilepsy. Epilepsia 1994;35(Suppl 3):S82.
38. Forsgren L, Edvinsson SO, Blomquist HK, et al: Epilepsy in a population of mentally retarded children and adults. Epilepsy Res 1990;6:234-248.
39. Meador KJ, Baker GA: Behavioral and cognitive effects of lamotrigine. J Child Neurol 1997;12(Suppl 1):S44-S47.
40. Whitman S, Herman BP, Gordon AC: Psychopathology in epilepsy: How great is the risk? Biol Psychiatry 1984;19:213-236.
41. Rush AJ, Frances A: Expert Consensus Guidelines Series: Treatment of psychiatric and behavioral problems in mental retardation. Am J Ment Retard 2000;105:159-226.
42. Borgeois BFD, Dodson WE: Antiepileptic and neurotoxic interactions between antiepileptic drugs, in Pitlick WH (ed): Antiepileptic Drug Interactions. New York, Demos, 1989, 209-218.
43. Guberman AH, Besag FM, Dooley JM, et al: Lamotrigine associated rash: Risk/benefit considerations in adults and children. Epilepsia 1999;40:985-991.
44. Ettinger AB, Wisrot DM, Saracco J, et al: Positive and negative psychotropic effects of lamotrigine in patients with epilepsy and mental retardation. Epilepsia 1998;39:874-877.
45. Beran RG, Gibson RJ: Aggressive behavior in intellectually challenged patients with epilepsy treated with lamotrigine. Epilepsia 1998;39:1018-1019.